Home » Stocks » URGN

UroGen Pharma Ltd. (URGN)

Stock Price: $17.57 USD -0.65 (-3.57%)
Updated May 10, 2021 2:26 PM EDT - Market open
Market Cap 406.28M
Revenue (ttm) 11.80M
Net Income (ttm) -128.48M
Shares Out 22.30M
EPS (ttm) -5.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $17.57
Previous Close $18.22
Change ($) -0.65
Change (%) -3.57%
Day's Open 18.08
Day's Range 17.30 - 18.62
Day's Volume 37,259
52-Week Range 17.01 - 30.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

UROGEN PHARMA (URGN) delivered earnings and revenue surprises of -5.34% and 10.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of UroGen Pharma (NASDAQ:URGN) rose 3.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 25.81% year over year to ($1.38), which missed...

1 month ago - Benzinga

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

1 month ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

1 month ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

1 month ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

1 month ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseas...

2 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disease...

2 months ago - Business Wire

PRINCETON, N.J. & HOUSTON--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urol...

3 months ago - Business Wire

UroGen's Jelmyto, approved April 2020 for LG-UTUC, has a J code effective 1/1/2021 allowing for dramatically more convenient coding & reimbursement. Revenues should be about $115,000/patient as labelled...

3 months ago - Seeking Alpha

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseas...

4 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

5 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseas...

5 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) today announced final topline results from the single-arm, open-label OPTIMA II Phase 2b trial evaluating the efficacy and safety of i...

5 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

5 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseas...

6 months ago - Business Wire

UroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Shares of UroGen Pharma (NASDAQ:URGN) were unchanged after the company reported Q3 results.

6 months ago - Benzinga

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

6 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

6 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve...

7 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd.

8 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd.

8 months ago - Business Wire

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Other stocks mentioned: BYSI, GTHX, KPTI
8 months ago - Seeking Alpha

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Other stocks mentioned: BYSI, GTHX, KPTI
8 months ago - Seeking Alpha

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd.

9 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd.

9 months ago - Business Wire

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

UroGen Is A Compelling Value With Recent FDA Approval

1 year ago - Seeking Alpha

Whether or not a recovery is imminent, there are compelling stocks to buy, it’s just a matter of where you look for them.

Other stocks mentioned: AMRC, CATM, EHTH, GWPH, HCA, QSR
1 year ago - InvestorPlace

Shares of UroGen Pharma Ltd. gained 10.7% in premarket trading on Thursday after the Food and Drug Administration approved the company's urothelial cancer treatment the night before.

1 year ago - Market Watch

UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

UroGen Pharma Ltd. (URGN) CEO Elizabeth Barrett on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Investors walked away from UroGen Pharma after an article was published by a short-seller, but clinical results appear to favor the company.

1 year ago - The Motley Fool

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Should you follow in their footsteps?

Other stocks mentioned: CTL, ECA
1 year ago - The Motley Fool

A major milestone gets closer with each passing day, but the stock seems to keep heading lower.

1 year ago - The Motley Fool

UroGen Pharma Ltd. (URGN) has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Wall Street, and most investors who follow its lead, is overlooking this online bank, pharmaceutical company, and master limited partnership. Investors who are paying attention could score outsized gain...

Other stocks mentioned: ALLY, NBLX
1 year ago - The Motley Fool

Axsome Therapeutics, Flexion Therapeutics, and UroGen Pharma gave investors reasons for excitement.

Other stocks mentioned: AXSM, FLXN
1 year ago - The Motley Fool

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

This Canadian midstream company, Canadian winter clothing manufacturer, and Israel-based pharma company could soon be making names for themselves in the U.S.

Other stocks mentioned: GOOS, PBA
2 years ago - The Motley Fool

This Israeli-based pharma company is poised to receive regulatory approval for its first product in the second half of 2019.

2 years ago - The Motley Fool

About URGN

UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma ... [Read more...]

Industry
Biotechnology
IPO Date
May 4, 2017
CEO
Elizabeth Barrett
Employees
187
Stock Exchange
NASDAQ
Ticker Symbol
URGN
Full Company Profile

Financial Performance

In 2020, UroGen Pharma's revenue was $11.80 million, an increase of 65,450.00% compared to the previous year's $18,000. Losses were -$128.48 million, 22.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for UroGen Pharma stock is "Buy." The 12-month stock price forecast is 39.67, which is an increase of 125.78% from the latest price.

Price Target
$39.67
(125.78% upside)
Analyst Consensus: Buy